The future of medicine lies within us.
At Ensoma, we develop one-time in vivo treatments that precisely engineer any or all blood and immune cells to cure diseases from within.
Through the Engenious™ platform, Ensoma is expanding the boundaries of gene therapy – from rare monogenic illnesses to prevalent polygenic conditions such as autoimmune disease and cancer that affect millions around the world.
Science has greatly advanced our understanding of the complex dysfunction underlying disease and the role played by blood and immune cells in that dysfunction. Despite this knowledge, we have lacked a unified approach that could address this complexity with the full genetic toolkit. That changes now.
Engenious therapies have an unmatched capacity to deliver all modern genetic modification tools to any or all blood and immune cells. That means smarter cells for curative therapies.
